Collegium Pharmaceutical, Inc. Sale of Stock, Consideration Received on Transaction
Collegium Pharmaceutical, Inc. (COLL) reported Sale of Stock, Consideration Received on Transaction of $34.28 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2020-02-27
- Collegium Pharmaceutical, Inc. sale of stock, consideration received on transaction for the quarter ending 2018-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. sale of stock, consideration received on transaction for the quarter ending 2018-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. sale of stock, consideration received on transaction for the quarter ending 2018-03-31 was $34.28M.
- Collegium Pharmaceutical, Inc. sale of stock, consideration received on transaction for the quarter ending 2017-12-31 was $22.83M.
- Collegium Pharmaceutical, Inc. sale of stock, consideration received on transaction for fiscal 2017 was $34.28M.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $34.28M 10-Q · filed 2018-11-08 | $57.11M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $34.28M 10-Q · filed 2018-08-08 | $57.11M derived: sum of 3 quarters · filed 2020-02-27 | ||
| 2018-03-31 | $34.28M 10-Q · filed 2018-05-09 | $57.11M derived: sum of 2 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $22.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $34.28M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | $11.46M 10-Q · filed 2017-11-08 | ||||
| 2016-10-31 | $86.17M 10-Q · filed 2017-11-08 | ||||
| 2016-01-31 | $51.17M 10-Q · filed 2017-11-08 | ||||
| 2015-03-31 | $44.81M 10-Q/A · filed 2015-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |